Brief: Biofrontera Announces FDA Filing Acceptance Of Supplemental New Drug Application For Ameluz® Pdt In Superficial Basal Cell Carcinoma
11/02/2026 14:31
Feb 11 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA ANNOUNCES FDA FILING ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN SUPERFICIAL BASAL CELL CARCINOMA BIOFRONTERA INC - FDA SETS PDUFA DATE FOR SEPTEMBER 28, 2026 Source text: ID:nGNX5vtFRL Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales